Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CARDIOVASCULAR COMPLICATIONS OF DIABETES-MELLITUS - WHAT WE KNOW AND WHAT WE NEED TO KNOW ABOUT THEIR PREVENTION
Autore:
SAVAGE PJ;
Indirizzi:
NHLBI,EPIDEMIOL & BIOMETRY PROGRAM,DECA,2 ROCKLEDGE CTR,RM 8154,6701 ROCKLEDGE DR BETHESDA MD 20892
Titolo Testata:
Annals of internal medicine
fascicolo: 1, volume: 124, anno: 1996,
parte:, 2
pagine: 123 - 126
SICI:
0003-4819(1996)124:1<123:CCOD-W>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY HEART-DISEASE; RISK-FACTORS; POPULATION; MORTALITY; FRAMINGHAM; PROGRAM; ONSET; MEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
P.J. Savage, "CARDIOVASCULAR COMPLICATIONS OF DIABETES-MELLITUS - WHAT WE KNOW AND WHAT WE NEED TO KNOW ABOUT THEIR PREVENTION", Annals of internal medicine, 124(1), 1996, pp. 123-126

Abstract

Cardiovascular disease is a major cause of morbidity and mortality inpatients with non-insulin-dependent diabetes mellitus (NIDDM). With an increase in the number of older diabetic persons, an increase in U.S. minority populations with high rates of diabetes, and the proven success of new methods to reduce microvascular complications, the importance of diabetic macrovascular complications will increase. The relative effectiveness of different treatments to reduce the incidence of diabetic cardiovascular complications is poorly understood. In addition to relative efficacy, issues related to patient burden and the economiccost of different treatments must be considered. Some of the information needed to improve therapy will be available soon from ongoing clinical trials. Obtaining definitive answers to other questions, especially those related to the relative benefit of intensive glucose level control compared with control of other known cardiovascular disease riskfactors, will require additional studies. Although several questions unique to diabetic patients remain unanswered, results of previous clinical trials done among largely nondiabetic participants can be used to develop interim recommendations for cardiovascular disease prevention. Until definitive guidelines for prevention are established, combining aggressive therapy for known cardiovascular disease risk factors with efforts to normalize the glucose level offers the best chance to reduce the higher risk for cardiovascular disease associated with NIDDM.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 00:46:45